Mycrudex 后 SALPS 跟随

StephenW

Public release date: 2-Apr-2011
[Print  | E-mail | Share] [ Close Window ]

Contact: Travis Taylor
[email protected]
44-784-306-9451
European Association for the Study of the Liver
Entry inhibitors show promise as drugs with new MOA for treatment of HBV and HDV infectionFirst new hepatitis B and D treatment for many years        Berlin, Germany, Saturday 02 April 2011: Promising new viral hepatitis data presented today at the International Liver CongressTM show that entry inhibitors --a new mechanism of action for drugs to treat viral hepatitis -- could provide the first new hepatitis B and hepatitis D treatments for many years.1,2
        Most current approved therapies directly target viral replication (e.g. nucleotide/side analogues), and can lead to the development of viral resistance or viral rebound after the end of treatment. Entry inhibitors prevent the virus from entering the cell and forming a stable replication complex, limiting the issue of viral rebound and resistance development.
        Professor Heiner Wedemeyer, EASL's Secretary General, commented: "The current treatments available for hepatitis B & D are limited. These novel drugs are the first promising treatments for many years. The shift in the mechanism of action of these drugs   from inhibiting the virus's replication directly to inhibiting its entry into the cell, and thus its replication – means they are less likely to produce viral resistance; a huge problem faced by many of today's clinicians."
        One study1 showed that treatment of ex-vivo liver cells with synthetic anti-lipopolysaccharide peptides (SALPs) during and prior to HBV infection was highly effective and dose dependent in inhibiting infection – reducing markers of HBV infection (e.g. HBV RNA, HBV antigens) in the concentration range of 4-5 µg/mL by 90% and 0.5-2 µg/mL by 50%.
        The study also demonstrated that SALPs showed activity against other viral (e.g. HIV, herpes) and microbial (e.g. peritonitis, colitis and pneumonia) infections. Therefore, SALPs represent a very promising therapeutic strategy to treat viral hepatitis infection and concomitant bacterial infection – which often leads to life threatening systematic complications.
        Other studies2,3 illustrated the enormous value of the chimaeric mouse model  of chronic HBV and HDV infection for the preclinical evaluation of antiviral drugs. The study demonstrated that the HBV entry inhibitor Myrcludex-B was able to completely block the spread of HBV from cell to cell and to prevent de-novo HDV infection of human hepatocytes.
        Professor Wedemeyer commented: "Although there are 35 million people around the world with HDV infection there is currently little to offer them therapeutically. I am therefore delighted to see these new drug developments."
       

###

        Notes to Editors
                Notes to Editors
        About EASL
EASL is the leading European scientific society involved in promoting research and education in hepatology. EASL attracts the foremost hepatology experts and has an impressive track record in promoting research in liver disease, supporting wider education and promoting changes in European liver policy.
        EASL's main focus on education and research is delivered through numerous events and initiatives, including:

• The International Liver CongressTM which is the main scientific and professional event in hepatology worldwide
• Meetings including Monothematic and Special conferences, Post Graduate courses and other endorsed meetings that take place throughout the year
• Clinical and Basic Schools of Hepatology, a series of events covering different aspects in the field of hepatology
• Journal of Hepatology published monthly
• Participation in a number of policy initiatives at European level
  

        About The International Liver CongressTM 2011
The International Liver Congress™ 2011, the 46th annual meeting of the European Association for the study of the Liver, is being held at the Internationales Congress Centrum, Berlin, Germany from March 30 – April 3, 2011. The congress annually attracts over 7,500 clinicians and scientists from around the world and provides an opportunity to hear the latest research, perspectives and treatments of liver disease from principal experts in the field.
        References
1.  Lucifora J et al. Novel peptide-based microbiocides inhibiting hepatitis b virus entry by preventing virus interaction with the cell surface. Abstract presented at The International Liver CongressTM 2011. http://www1.easl.eu/easl2011/program/Orals/338.htm
        2.  Lutgehetmann M et al. Block of hepatitis delta infection by the entry inhibitor myrcludex b in upa mice: establishment of an efficient mouse model for human HBV/HDV infection. Abstract presented at The International Liver CongressTM 2011. http://www1.easl.eu/easl2011/program/Orals/390.htm
        3.  Ben M et al. Administration of the entry inhibitor Myrcludex-B after establishment of Hepatitis B Virus infection prevents viral spreading among human hepatocytes in uPA mice. Abstract presented at The International Liver CongressTM 2011. http://www1.easl.eu/easl2011/program/Orals/337.htm

StephenW

公开发布日期：2月2011年
[打印|邮箱|分享分享] [关闭窗口]

联系人：特拉维斯泰勒
[email protected]
44-784-306-9451
欧洲协会肝脏研究
进入抑制剂与显示为HBV和HDV感染的治疗药物新的协议备忘录的承诺
第一个新的治疗B型肝炎和D多年

德国柏林，2011年4月2日星期六：病毒性肝炎有前途的新数据发表在国际肝病CongressTM展今天进入抑制剂 - 一种用于治疗肝炎的药物作用的新机制 - 第一个新的能够提供乙型肝炎和丁型肝炎许多years.1治疗，2

目前，多数批准的治疗直接针对病毒复制（如核苷酸/侧类似物），可以导致病毒耐药或病毒反弹，在治疗结束后的发展。进入抑制剂阻止进入细胞并形成稳定的复制复合物，限制了病毒反弹和抵抗病毒的发展问题。

教授海纳魏德迈，欧洲肝病学会的秘书长说：“目前治疗乙型肝炎的研发是有限的这些新的药物是多年来第一个有前途的治疗，从抑制了这些药物的作用机制转变病毒的复制。。直接抑制其进入细胞，因此它的复制 - 意味着他们不太可能产生病毒的抵抗力;由一个巨大的问题，今天的许多临床医生面临“。

一位研究1表明，与合成抗内毒素肽（SALPs）前活体肝细胞治疗期间及之前的HBV感染是非常有效和剂量依赖性抑制感染 - 减少乙肝病毒感染（如乙肝病毒核糖核酸，乙肝病毒抗原）标记在在4-5微克/ 90％和0.5〜2微克/毫升毫升50％浓度范围。

这项研究还表明，SALPs表明对其他病毒（如艾滋病毒，疱疹）和微生物（如腹膜炎，肠炎，肺炎）感染的活动。因此，SALPs代表一个非常有前途的治疗方法来治疗病毒性肝炎感染和随之而来的细菌感染 - 这通常会导致危及生命系统的并发症。

其他studies2，3所示为抗病毒药物的临床前评价的慢性HBV和HDV感染的嵌合小鼠模型的巨大价值。研究表明，乙肝病毒进入抑制剂Myrcludex - B是能够完全阻止病毒从细胞到细胞扩散和防止德伏HDV感染的人肝细胞。

魏德迈教授说：“虽然与HDV感染有3500万世界各地的人们目前还没有为他们提供治疗学因此，我很高兴地看到这些新药物的发展。。”

＃＃＃

编者注

编者注

关于欧洲肝病学会

欧洲肝病学会是欧洲领先的科学学会，在促进肝脏病学研究和教育工作。欧洲肝病学会吸引首要肝脏病专家，具有促进肝脏疾病的研究，支持和促进在更广泛的教育政策的变化令人印象深刻的欧洲肝脏纪录。

欧洲肝病学会的教育和研究的重点是通过各种活动和提供措施，包括：

    *国际肝脏CongressTM这是主要的科学和专业的全球肝病学事件
    *包括Monothematic会议和特别会议，研究生课程及其他会议，通过采取全年地方
    *临床与基础学校的肝脏，一个覆盖在肝脏病学领域的不同方面的一系列事件
    *肝脏病杂志每月公布
    *在多项政策在欧洲一级的参与

关于2011年国际肝病CongressTM

国际肝病会议™2011年，第46届欧洲协会的年度会议，为肝脏研究，是被关押在Internationales国会善存，柏林，德国从三月30号至4月3号，2011年。大会每年吸引来自世界各地的临床医生和科学家超过7500，提供了一个机会听到的最新研究成果，观点和肝脏疾病的治疗从该领域的主要专家。

参考文献

1。 Lucifora J等人。新型肽为基础的杀微生物抑制乙型肝炎病毒的预防与病毒进入细胞表面的相互作用。摘要发表在国际肝病CongressTM 2011年。 http://www1.easl.eu/easl2011/program/Orals/338.htm

2。 Lutgehetmann M等人。块型肝炎感染的进入抑制剂在小鼠myrcludex乌帕乙：一个人的乙肝病毒/ HDV感染小鼠模型的建立高效率。摘要发表在国际肝病CongressTM 2011年。 http://www1.easl.eu/easl2011/program/Orals/390.htm

3。本M等人。在进入抑制剂Myrcludex - B的给药后乙型肝炎病毒感染之间建立防止病毒在人肝细胞中uPA小鼠蔓延。摘要发表在国际肝病CongressTM 2011年。 http://www1.easl.eu/easl2011/program/Orals/337.htm

非东亚病夫

快点临床才是硬道理~！